Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
February 18, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
February 12, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
January 13, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
- INNATE is a robust Phase 1 study designed to dose escalate quickly and demonstrate proof of concept for JTX-8064 monotherapy and PD-1i combinations - - Tumor-specific expansion cohorts to...
Jounce Therapeutics to Present at Upcoming Investor Conferences in January
January 08, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Added to NASDAQ Biotechnology Index
December 16, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 25, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism
November 16, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
-Phase 1 INNATE trial will evaluate JTX-8064 as a monotherapy and in combination with Jounce’s PD-1 inhibitor, JTX-4014- -On track to begin enrollment by year-end 2020- CAMBRIDGE, Mass., Nov. 16,...
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the Society for Immunotherapy of Cancer’s (SITC) 35th Annual Meeting
November 11, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
-Preclinical data highlight Jounce’s approach to identify potential predictive and pharmacodynamic biomarkers to identify patients who may benefit from JTX-8064- -Enrollment in Phase 1 monotherapy...
Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit
November 09, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Third Quarter 2020 Financial Results
November 06, 2020 07:00 ET
|
Jounce Therapeutics, Inc.
-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for JTX-1811- -Initiated the Phase 2 SELECT...